Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16762027 | 0.88 | FOLH1 (0.43) | ALDH1A1HPGDGAAPOLBFOLH1 | |
| SCHEMBL16762058 | 0.86 | SMN1; SMN2 (0.53) | ALDH1A1RAB9AGAAPOLBFOLH1 | |
| SCHEMBL16762156 | 0.85 | FOLH1 (0.41) | ALDH1A1TSHRGAAPOLBFOLH1 | |
| SCHEMBL23357781 | 0.85 | CTSK (0.52) | ALDH1A1TSHRHPGDGAA | |
| SCHEMBL8828162 | 0.85 | CTSK (0.52) | ALDH1A1TSHRHPGDGAA | |
| SCHEMBL16762032 | 0.84 | POLB (0.46) | ALDH1A1TSHRHPGDPOLBPKM | |
| SCHEMBL6122744 | 0.84 | FOLH1 (0.43) | ALDH1A1HPGDGAAPOLBFOLH1 | |
| SCHEMBL16762002 | 0.83 | POLB (0.45) | ALDH1A1TSHRHPGDPOLBSMN1; SMN2 | |
| SCHEMBL6123149 | 0.82 | ALDH1A1 (0.48) | ALDH1A1TSHRGAAPOLBFOLH1 | |
| SCHEMBL16762202 | 0.82 | FOLH1 (0.52) | FOLH1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220001009-A1 | NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND | 7 Hills Pharma LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2019-07-11 | — | — | US | disclosed |
| US-10342866-B2 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | 7 HILLS INTERESTS LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3388429-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-09-11 | — | — | US | disclosed |
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2640721-B1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2881392-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2881393-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20170044130-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2017-02-16 | — | — | US | disclosed |
| US-20160339098-A1 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | 7 HILLS PHARMA INC. | 2016-11-24 | — | — | US | disclosed |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-12-24 | — | — | US | disclosed |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-10-15 | — | — | US | disclosed |
| EP-2881392-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881393-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2640721-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068251-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | ALDH1A1 740/4885TSHR 396/4885HPGD 3157/4885 |
| US-20220001009-A1 | NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND | CD47, ITGB1, ITGAM | ALDH1A1 2925/4885TSHR 1992/4885HPGD 3851/4885 |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | ALDH1A1 725/4885TSHR 430/4885HPGD 3100/4885 |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | ALDH1A1 755/4885TSHR 405/4885HPGD 3045/4885 |
| US-20170044130-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | ALDH1A1 755/4885TSHR 405/4885HPGD 3045/4885 |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | ALDH1A1 740/4885TSHR 396/4885HPGD 3157/4885 |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | ALDH1A1 740/4885TSHR 396/4885HPGD 3157/4885 |
| US-10342866-B2 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | CD4, ICOS, CD274 | ALDH1A1 3592/4885TSHR 220/4885HPGD 4295/4885 |
| US-20160339098-A1 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | CD4, CD274, ICOS | ALDH1A1 3675/4885TSHR 171/4885HPGD 4320/4885 |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | ALDH1A1 740/4885TSHR 396/4885HPGD 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.